Metabolic syndrome and aortic stiffness

Czech version

Authors: A. Šimková ¹; J. Bulas ¹; J. Murín ¹; K. Kozlíková ²; I. Janiga ³
Authors‘ workplace: I. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednostka doc. MU Dr. Soňa Kiňová, PhD. ¹; Ústav lekárskej fyziky, biofyziky, informatiky a telemedicíny Lékárskej fakulty UK Bratislava, Slovenská republika, prednostka prof. MU Dr. Elena Kukurová, CSc. ²; Slovenská technická univerzita Bratislava, Slovenská republika, dekan prof. Ing. Ľubomír Šóoš, PhD. ³
Published in: Vnitř Lék 2010; 56(9): 1000-1004
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Overview

Introduction:
The metabolic syndrome (MS) is a cluster of risk factors that move the patient into higher level of risk category of cardiovascular disease and the probability of type 2 diabetes mellitus manifestation. Definition of MS is s based on the presence of selected risk factors as: abdominal obesity (lager waist circumpherence), atherogenic dyslipidemia (low value of HDL‑cholesterol and increased level of triglycerides), increased fasting blood glucose (or type 2 DM diagnosis), higher blood pressure or antihypertensive therapy. In 2009 there were created harmonizing criteria for MS definition; the condition for assignment of MS is the presence of any 3 criteria of 5 mentioned above. The underlying disorder of MS is an insulin resistance or prediabetes. The patients with MS more frequently have subclinical (preclinical) target organ disease (TOD) which is the early sings of atherosclerosis. Increased aortic stiffness is one of the preclinical diseases and is defined by pathologically increased carotidofemoral pulse wave velocity in aorta (PWV Ao).

With the aim to assess the influence of MS on aortic stiffness we examined the group of women with arterial hypertension and MS and compare them with the group of women without MS.

Patient and methods:

The aortic stiffness was examined by Arteriograph – Tensiomed, the equipment working on the oscillometric principle in detection of pulsations of brachial artery. This method determines the global aortic stiffness based on the analysis of the shape of pulse curve of brachial artery.

Results:
From the cohort of 49 pts 31 had MS, the subgroups did not differ in age or blood pressure level. The mean number of risk factors per person in MS was 3.7 comparing with 1.7 in those without MS. In the MS group there was more frequently abdominal obesity present (87% vs 44%), increased fasting bood glucose (81% vs 22%) and low HDL‑cholesterol level. The pulse wave velocity in aorta, PWV Ao, was significantly higher in patients with MS (mean value 10,19 m/ s vs 8,96 m/ s without MS).

Conclusion:
The higher PWV Ao indicates a higher aortic stiffness in patients with MS and more severe subclinical target organ damage of cardiovascular system.

Key words:
metabolic syndrome – risk factors – aortic stiffness – pulse wave velocity in aorta – preclinical cardiovascular disease

Sources

1. Ninomiya JK, L’Italien G, Criqui MH et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42– 46.

2. Souček M. Metabolický syndrom. Vnitř Lék 2009; 55: 618– 621.

3. Pella D, Mechírová V. Manažment artériovej hypertenzie pri metabolickom syndróme. Via Practica 2007; 4 (Suppl 4): 19– 22.

4. Executive summary of the third report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486– 2497.

5. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735– 2752.

5. Tkáč I, Klimeš I, Mikeš Z et al. Nové odporúčania panelu expertov. Diagnóza a možnosti liečebného ovplyvnenia metabolického syndrómu. Súč Klin Pr 2005; 1: 12– 15.

6. International Diabetes Federation definition of the metabolic syndrome. Available from: www.idf.org.

7. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of obesity. Circulation 2009; 120: 1640– 1645.

8. Grassi G. Obesity, target organ damage and cardiovascular risk. E- journal of cardiology practice 2008; 7: 1– 3.

9. Filipová S. Manažment pacientov s vysokým kardiometabolickým rizikom 2.časť – dlhodobé liečebné ovplyvnenie pacientov s vysokým kardiometabolickým rizikom – súčasné trendy. Interná Med 2007; 7: 439– 443.

10. Willum- Hansen T, Staessen JA, Torp-Pedersen C et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664– 670.

11. Kullo IJ, Bielak LF, Turner ST et al. Aortic pulse wave velocity is associated with the presence and quantity of coronary artery calcium: a community‑based study. Hypertension 2006; 47: 174– 179.

12. Weber T, Auer J, O’Rourke MF et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109: 184– 189.

13. Nürnberger J, Keflioglu‑ Scheiber A, Opazo Saez AM. Augmentation index is associated with cardiovascular risk. J Hypertens 2002; 20: 2407– 2414.

14. Farský Š. Cievna stena vzhľadom na nové odporúčania pre diagnostiku a liečbu hypertenzie. Cardiol 2008; 17: K/ C24– K/ C25.

15. Baulmann J, Schillings U, Rickert S et al. A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo‑ electronic methods. J Hypertens 2008; 26: 523– 528.

16. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588– 2605.

17. Standl E. Aetiology and consequence of the metabolic syndrome. Eur Heart J Suppl 2005; 7 (Suppl D): D10– D13.

18. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta‑analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403– 414.

19. Dukát A. Metabolický syndróm predstavuje dnes jeden z najdôležitejších problémov súčasnej medicíny. Súč Klin Pr 2004; 3: 5– 8.

20. Souček M. Úvod do problematiky metabolického syndromu. Vnitř Lék 2005; 51: 48– 52.

21. Balkau B. Epidemiology of the metabolic syndrome and the RISC study. Eur Heart J Suppl 2005; 7 (Suppl D): D6– D9.

22. Song Y, Manson J, Meigs J et al. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10‑year risk of cardiovascular events in women. Am J Cardiol 2007; 100: 1654– 1658.

23. Galajda P, Mokáň M, Prídavková D et al. Prevalencia metabolického syndrómu na Slovensku. Interná Med 2007; 7: 325– 331.

24. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374– 381.

25. Rybka J. Prediabetes 2009. Vnitř Lék 2009; 55: 819– 826.

26. Dukát A, Lietava J, Krahulec B et al. IDEA – prvé výsledky o prevalencii abdominálnej obezity na Slovensku. Via Pract 2006; 3: 554– 557.

27. Van Bortel LM, Duprez D, Starmans‑ Kool MJ et al. Clinical applications of arterial stiffness, Task Force III: Recommendations for user procedures. Am J Hypertens 2002; 15: 445– 452.

28. Miklos I. A new and fast screening method for measuring complex hemodynamical parameters and arterial stiffness noninvasively with a simple arm cuff. Am J Hypertens 2005; 18: 15A.

29. Jatoi NA, Mahmud A, Bennett K et al. Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronis (Complior) and tonometric (SphygmoCor) techniques. J Hypertens 2009; 27: 2186– 2191.

30. Boutouyrie P, Revera M, Parati G. Obtaining arterial stiffness indices from simple arm cuff measurements: the holy grail? J Hypertens 2009; 27: 2159– 2161

31. Vyssoulis GP, Pietri PG, Karpanou EA et al. Differential impact of metabolic syndrome on arterial stiffness and wave reflections: Focus on distinct definitions. Int J Cardiol 2010; 138: 119– 125.

32. Roes SD, Alizadeh Dehnavi R, Westenberg JJ et al. Assessment of aortic pulse wave velocity and cardiac diastolic function in subjects with and without the metabolic syndrome: HDL cholesterol is independently associated with cardiovascular function. Diabetes Care 2008; 31: 1442– 1444.